← Back

Actavis

Leading global specialty pharmaceutical company manufacturing generic and over the counter (OTC) products.

From the start of its involvement in 1999 when the original Bulgarian company had revenues of $100m, Novator took the long view, guiding and advising the business through multiple mergers and acquisitions and a privatisation building the revenue to $15bn.

Sold to Watson in 2012. Novator exited fully in 2016.